ALK and non-small cell lung carcinoma: The latest released data for East Asian patients in PROFILE 1029 revealed that median PFS was 11.1 (95% confidence interval, CI: 8.3–12.6) months for first-line crizotinib-treated advanced ALK(+) NSCLC patients (7).